FocusOn Neurology
  • Biozone
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
    • Peer-reviewed articles
    • Supplemental educational content
    • Test Your Knowledge

Advanced Search

Advanced Search

  • Featured:
  • Biozone
  • Myasthenia Gravis

Remission of myasthenia gravis following infection with SARS-CoV-2

Aug 28, 2025

Share:
Back to Myasthenia Gravis Peer-reviewed articles

Read Full Article

Abstract

This case report describes an unprecedented remission of ocular Myasthenia Gravis (MG) in a 3-year-old girl following a SARS-CoV-2 infection. Both MG and SARS-CoV-2 influence the cholinergic system, and this case underscores the importance of considering multiple factors in autoimmune disorders and the potential impact of viral infections on their course. The patient initially presented with ptosis and limited eye movement. Her diagnosis of seronegative MG was confirmed with abnormal visual evoked potentials and positive response to pyridostigmine. Her ptosis and limited extraocular muscle movement were intermittent until 2 years later when she tested positive for SARS-CoV-2 for which no antiviral medication was taken. Unexpectedly, her MG symptoms rapidly improved postinfection, leading to the cessation of pyridostigmine. This case highlights the complex interplay between MG, viral infections, and the influence of anti-acetylcholine receptor antibodies, second-hand smoke, and natural nicotinic agonists from the use of pyridostigmine on the cholinergic system.
Share

Modal body text goes here.

FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More